Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study
暂无分享,去创建一个
Alexander Y. Trick | S. Meltzer | J. Abraham | A. Stark | E. Shin | M. Khashab | S. Kambhampati | Yulan Cheng | S. Ngamruengphong | Yulong He | Tza-Huei Wang | H. Tsai | Hao Wang | V. Prasath | C. Şimşek | M. Duncan | A. Trick | Zhixiong Wang | K. Ma | Alan H. Tieu | Xi Liu
[1] Herbert C. Wolfsen,et al. Highly Discriminant Methylated DNA Markers for the Non‐endoscopic Detection of Barrett's Esophagus , 2018, The American Journal of Gastroenterology.
[2] T. LaFramboise,et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus , 2018, Science Translational Medicine.
[3] M. O’Donovan,et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens , 2017, Gut.
[4] A. Chak,et al. Global DNA methylation patterns in Barrett’s esophagus, dysplastic Barrett’s, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use , 2016, Clinical Epigenetics.
[5] J. Herman,et al. Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum , 2016, Clinical Cancer Research.
[6] Kenneth K Wang,et al. Screening for Barrett's Esophagus. , 2015, Gastroenterology.
[7] Sarmed S. Sami,et al. Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control Study , 2015, PLoS medicine.
[8] H. El‐Serag,et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus , 2014, Gut.
[9] J. Jankowski,et al. Trefoil Factor Expression in a Human Model of the Early Stages of Barrett’s Esophagus , 2015, Digestive Diseases and Sciences.
[10] Tza-Huei Wang,et al. The promise of methylation on beads for cancer detection and treatment , 2014, Expert review of molecular diagnostics.
[11] A. Gavin,et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study , 2014, Gut.
[12] Tza-Huei Wang,et al. Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[13] S. Spechler,et al. Barrett esophagus and risk of esophageal cancer: a clinical review. , 2013, JAMA.
[14] J. Davison,et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). , 2012, Gastrointestinal endoscopy.
[15] R. Fitzgerald,et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. , 2012, Gastrointestinal endoscopy.
[16] H. Sørensen,et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. , 2011, The New England journal of medicine.
[17] Trevor Hastie,et al. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.
[18] Paul K Crane,et al. lordif: An R Package for Detecting Differential Item Functioning Using Iterative Hybrid Ordinal Logistic Regression/Item Response Theory and Monte Carlo Simulations. , 2011, Journal of statistical software.
[19] Bin Wang,et al. Deconvolution Estimation in Measurement Error Models: The R Package decon. , 2011, Journal of statistical software.
[20] Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study , 2011, BMJ : British Medical Journal.
[21] J. Emery,et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study , 2010, BMJ : British Medical Journal.
[22] G. Falk,et al. Brush cytology vs. endoscopic biopsy for the surveillance of Barrett's esophagus. , 2010, Endoscopy.
[23] Yi Zhang,et al. Single-tube analysis of DNA methylation with silica superparamagnetic beads. , 2010, Clinical chemistry.
[24] B. Reid,et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.
[25] G. Lyratzopoulos,et al. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. , 2009, Gastroenterology.
[26] A. Bhattacharyya,et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. , 2009, Cancer research.
[27] D. Beer,et al. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors , 2008, International journal of cancer.
[28] W. Chow,et al. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.
[29] J. G. de Groot,et al. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens , 2008, Genes, chromosomes & cancer.
[30] Tetsuo Ito,et al. Hypermethylation of the AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic Progression , 2008, Cancer Epidemiology Biomarkers & Prevention.
[31] F. Sato,et al. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis , 2008, Cancer.
[32] D. Beer,et al. Hypermethylation of Tachykinin-1 Is a Potential Biomarker in Human Esophageal Cancer , 2007, Clinical Cancer Research.
[33] Tetsuo Ito,et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma , 2007, Oncogene.
[34] M. Brock,et al. The use of “overall accuracy” to evaluate the validity of screening or diagnostic tests , 2004, Journal of General Internal Medicine.
[35] J. Hunter,et al. Office-Based Unsedated Small-Caliber Endoscopy Is Equivalent to Conventional Sedated Endoscopy in Screening and Surveillance for Barrett's Esophagus: A Randomized and Blinded Comparison , 2006, The American Journal of Gastroenterology.
[36] H. Wolfsen,et al. Barrett's Esophagus Is Common in Older Men and Women Undergoing Screening Colonoscopy Regardless of Reflux Symptoms , 2006, The American Journal of Gastroenterology.
[37] M. Pepe,et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk , 2005, Oncogene.
[38] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[39] G. Falk. Cytology in Barrett's esophagus. , 2003, Gastrointestinal endoscopy clinics of North America.
[40] A. Fendrick,et al. Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A CostUtility Analysis , 2003, Annals of Internal Medicine.
[41] Sushovan Guha,et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. , 2002, Gastroenterology.
[42] A. Sonnenberg,et al. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? , 2000, American Journal of Gastroenterology.
[43] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[44] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[45] S. Hamilton,et al. Diagnostic value of cytopathology in Barrett esophagus and associated carcinoma. , 1988, American journal of clinical pathology.
[46] S. Witte. [Cytologic diagnosis of the upper gastrointestinal tract]. , 1984, Leber, Magen, Darm.